Bexobrutideg (NX-5948) is an orally active chimeric targeting molecule (CTM) that induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. Bexobrutideg mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. Bexobrutideg is efficacious in a mouse collageninduced arthritis (CIA) model. Bexobrutideg can cross the blood brain barrier (BBB). Bexobrutideg is a PROTAC composed of the ligand for target protein, a linker, and a cereblon E3 ligase (CRBN) complex (Red: BTK ligand (HY-170324), Blue: CRBN ligand (HY-171893), Black: linker)[1][2][3].
Molecular Weight:
806.96
Purity:
99.33
CAS Number:
[2649400-34-8]
Formula:
C42H54N12O5
Target:
Btk,PROTACs
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
